These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 23961597)

  • 21. Drug approved for type 2 diabetes.
    Nurs Times; 2014 Jul 2-8; 110(27):4. PubMed ID: 25095559
    [No Abstract]   [Full Text] [Related]  

  • 22. Empagliflozin (Jardiance) for diabetes.
    Med Lett Drugs Ther; 2014 Oct; 56(1453):99-100. PubMed ID: 25296258
    [No Abstract]   [Full Text] [Related]  

  • 23. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
    Nomura S; Sakamaki S; Hongu M; Kawanishi E; Koga Y; Sakamoto T; Yamamoto Y; Ueta K; Kimata H; Nakayama K; Tsuda-Tsukimoto M
    J Med Chem; 2010 Sep; 53(17):6355-60. PubMed ID: 20690635
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sodium-glucose cotransporter 2 inhibitors and diabetic ketoacidosis.
    Bloomgarden ZT
    J Diabetes; 2016 Mar; 8(2):175-6. PubMed ID: 26611882
    [No Abstract]   [Full Text] [Related]  

  • 25. [The role of SGLT-2 inhibitors in the treatment of type 2 diabetes].
    Rupprecht H
    MMW Fortschr Med; 2015 Jan; 157(1):55-8. PubMed ID: 25743304
    [No Abstract]   [Full Text] [Related]  

  • 26. C-aryl glucosides substituted at the 4'-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
    Xu B; Feng Y; Cheng H; Song Y; Lv B; Wu Y; Wang C; Li S; Xu M; Du J; Peng K; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Roberge JY; Seed B; Chen Y
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4465-70. PubMed ID: 21737266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. European Association for the Study of Diabetes 51st Annual Meeting.
    Gao HX; Regier EE; Close KL
    J Diabetes; 2016 Mar; 8(2):177-80. PubMed ID: 26606912
    [No Abstract]   [Full Text] [Related]  

  • 28. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
    Veltkamp SA; van Dijk J; Collins C; van Bruijnsvoort M; Kadokura T; Smulders RA
    Clin Ther; 2012 Aug; 34(8):1761-71. PubMed ID: 22795925
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Canagliflozin, alogliptin benzoate, and ospemifene.
    Hussar DA; Frimpong JO
    J Am Pharm Assoc (2003); 2013; 53(4):442-7. PubMed ID: 23892821
    [No Abstract]   [Full Text] [Related]  

  • 30. Diuretic effects of sodium-glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and heart failure.
    Takeuchi T; Dohi K; Omori T; Moriwaki K; Sato Y; Nakamori S; Fujimoto N; Fujii E; Yamada N; Ito M
    Int J Cardiol; 2015 Dec; 201():1-3. PubMed ID: 26278671
    [No Abstract]   [Full Text] [Related]  

  • 31. Canagliflozin: a new hope in the antidiabetic armamentarium.
    Katsi VK; Michalakeas CA; Grassos CE; Vamvakou GD; Lekakis JP; Tousoulis D; Stefanadis CI; Makris TK; Kallikazaros IE
    Recent Pat Cardiovasc Drug Discov; 2013 Dec; 8(3):216-20. PubMed ID: 24359233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SGLT2 inhibitors for diabetes: turning symptoms into therapy.
    Diamant M; Morsink LM
    Lancet; 2013 Sep; 382(9896):917-8. PubMed ID: 23850056
    [No Abstract]   [Full Text] [Related]  

  • 33. [SGLT2 inhibition in type 2 diabetes. New study data for reducing cardiovascular risk].
    MMW Fortschr Med; 2015 Oct; 157(18):86-7. PubMed ID: 26985517
    [No Abstract]   [Full Text] [Related]  

  • 34. What is the place of new SGLT-2 inhibitors in therapy and on the formulary?
    Mehr SR; Zimmerman MP
    Am J Manag Care; 2014 Mar; 20(4 Spec No.):E1. PubMed ID: 25618509
    [No Abstract]   [Full Text] [Related]  

  • 35. Diabetes field cautiously upbeat despite possible setback for leading SGLT2 inhibitor.
    Jones D
    Nat Rev Drug Discov; 2011 Aug; 10(9):645-6. PubMed ID: 21878967
    [No Abstract]   [Full Text] [Related]  

  • 36. Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: discovery of YM543.
    Ikegai K; Imamura M; Suzuki T; Nakanishi K; Murakami T; Kurosaki E; Noda A; Kobayashi Y; Yokota M; Koide T; Kosakai K; Ohkura Y; Takeuchi M; Tomiyama H; Ohta M
    Bioorg Med Chem; 2013 Jul; 21(13):3934-48. PubMed ID: 23651509
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Type 2 diabetes mellitus and Invokana: an FDA approved drug.
    Akhtar N
    Curr Diabetes Rev; 2013 Nov; 9(6):478-90. PubMed ID: 24160357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ipragliflozin: first global approval.
    Poole RM; Dungo RT
    Drugs; 2014 Apr; 74(5):611-7. PubMed ID: 24668021
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Visualization of mechanism of action, and a further therapeutic potential of ipragliflozin, a selective SGLT2 inhibitor].
    Takasu T; Takakura S; Hamada K
    Nihon Yakurigaku Zasshi; 2016; 148(5):266-271. PubMed ID: 27803440
    [No Abstract]   [Full Text] [Related]  

  • 40. Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents.
    Washburn WN
    Expert Opin Ther Pat; 2009 Nov; 19(11):1485-99. PubMed ID: 19852718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.